astrazeneca plc said friday that its tezepelumab drug for treating eosinophilic esophagitisa rare chronic inflammatory diseasehas been granted orphan drug designation in the us the londonlisted biopharmaceutical company said tezepelumab is designed to treat eosinophilic esophagitisa disease that occurs when eosinophils